Laurus Labs Reports Robust 1H FY27 Growth Driven by CDMO Expansion
Laurus Labs Ltd · Investor Presentation · 29 Oct 2026, 8:48 pm
Laurus Labs Reports Robust 1H FY27 Growth Driven by CDMO Expansion Laurus Labs delivered strong 1H FY27 results, with revenue rising 31% YoY to ₹4,233 Cr, EBITDA jumping 72% YoY to ₹1,406 Cr (margins expanded 780 bps to 33.2%), and net profit increasing 126% YoY to ₹809 Cr. Growth was powered by CDMO small molecules (+77% YoY to ₹1,710 Cr). For Q2 FY27, revenue reached ₹2,206 Cr (+33% YoY) and PAT hit ₹441 Cr (+126% YoY). The company announced strategic acquisitions—a 60% stake in Galenvs and 52% in SI &C Resins—to enhance oligonucleotide and peptide capabilities, backed by a planned >₹3,000 Cr capex over FY27–FY28.
Original exchange filing (PDF)
More announcements from Laurus Labs Ltd
- Please see annexed enclosure. · 18 Nov 2026
- Please see annexed enclosure. · 11 Nov 2026
- Please see annexed enclosure. · 03 Nov 2026
- Please see enclosed annexure. · 30 Oct 2026
- Please see enclosed annexure · 29 Oct 2026
- Please see enclosed annexure · 29 Oct 2026
- Appointment of Mr. Kundan Kumar Jha as Joint Company Secretary of the Company w.e.f. November 1, 2026 · 29 Oct 2026
- Please see enclosed annexure · 29 Oct 2026
